Table 3.

Cox regression analysis of clinical and pathologic parameters in terms of LRC and PFS

	LRC		PFS
Univariate	HR	p-value	HR	p-value
T stage (continuous)	1.286	0.436	1.089	0.760
N stage (continuous)	0.704	0.284	0.804	0.504
HPV-negative	7.526	0.049	4.318	0.047
TPS ≥1%	1.515	0.367	1.056	0.899
TPS ≥10%	1.112	0.804	0.930	0.861
TPS ≥50%	1.042	0.956	0.862	0.843
SUV index wk0 (tumor-to-muscle) ≥1.89 (median)	1.243	0.612	1.520	0.312
SUV index wk2 (tumor-to muscle) ≥1.51 (median)	1.883	0.158	1.702	0.213
SUV index wk5 (tumor-to muscle) ≥1.31 (median)	0.715	0.460	0.450	0.725
No early hypoxia response (ΔSUV index wk0-2 ≥0)	3.111	0.011	2.487	0.035
No early hypoxia response + TPS ≥1%	3.374	0.022	2.752	0.052
Multivariate (backward elimination with likelihood ratio tests)
HPV-negative	2.936	0.305	1.637	0.517
No early hypoxia resolution (ΔSUV index wk0-2 ≥0)	1.217	0.799	0.996	0.996
No early hypoxia resolution + TPS ≥1%	3.374	0.022	2.752	0.052

Abbreviations: HPV = Human papillomavirus, TPS = Tumor proportional score, wk = week, SUV = standardized uptake value.